AEON Biopharma Business Summary

AEON Biopharma, Inc. (AEON) is a clinical-stage biopharmaceutical company that generates value through the development and future commercialization of its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA). Operating primarily within the neurosciences segment, the company utilizes a 351(k) biosimilar regulatory pathway to position ABP-450 as a direct competitor to BOTOX® (onabotulinumtoxinA) for multiple therapeutic indications, including cervical dystonia and chronic migraine. While currently pre-revenue, AEON’s business model focuses on securing regulatory approvals in global markets—having already achieved milestones in India and Mexico—and establishing a specialized U.S. commercial infrastructure for therapeutic neurotoxins. Direct competitors include AbbVie (Allergan), Revance Therapeutics, and Nektar Therapeutics; AEON distinguishes itself by pursuing a single FDA approval for all of BOTOX’s therapeutic indications, aiming to capture market share through clinical comparability and enhanced system affordability. The company was founded in 2012 by Robert E. Grant, former President of Allergan Medical, as an evolution of Alphaeon Corporation. The leadership team is currently led by President and CEO Rob Bancroft, who joined in April 2025 with over 25 years of experience, including senior roles at Revance Therapeutics and Allergan where he managed global BOTOX® strategies. Supporting the clinical pipeline is Chief Medical Officer Dr. Chad K. Oh, a veteran of UCLA and Revance with three decades of expertise in immunology and clinical development, alongside Chief Accounting Officer Jennifer Sy, who oversees financial operations following her tenure at Deloitte and Nogin. AEON is backed by notable strategic investor Daewoong Pharmaceutical Co., Ltd., which recently strengthened the company’s balance sheet through a significant debt-to-equity exchange, and its board includes former CEO Marc Forth and Chairman Jost Fischer.